Search This Blog

Tuesday, August 30, 2022

AMGEN: TOPLINE DATA FROM LUMAKRAS PHASE 3 TRIAL IN LUNG CANCER

 LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer

Detailed Data to be Presented at an Upcoming Medical Congress

https://www.prnewswire.com/news-releases/amgen-announces-topline-data-from-lumakras-sotorasib-phase-3-trial-in-non-small-cell-lung-cancer-301615013.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.